Literature DB >> 1425135

The current management of herpetic eye disease.

L M Collum1, W J Power, A Collum.   

Abstract

Herpes simplex disciform keratitis is a difficult condition. The general feeling is that it is an immune disease, mediated by the virus, possibly located in the endothelial cells. It is frequently combined with inflammation in the trabecular meshwork and with uveitis. There is some controversy in relation to treatment and it has been suggested that anti-virals will control herpetic disciform keratitis, particularly if the patient has never had steroids previously. The authors of this paper have, in the past, published data which showed that Acyclovir, with corticosteroid, was necessary in the management of disciform keratitis. The data suggested that Acyclovir on its own was not effective. It remained to be answered whether Acyclovir on its own would be effective in patients who never had steroids for any reason previously. This paper demonstrates clearly that it is necessary, irrespective of whether patients have had steroids in the past or not, to combine corticosteroids with Acyclovir in the management of herpetic disciform keratitis. Acyclovir, on its own, is shown to be ineffective. It has also been suggested that Acyclovir is non-toxic. In a general way this is true, but the authors suggest that Acyclovir ointment does produce a punctate keratitis in patients with tear film disease, and that oral Acyclovir is preferable in such patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425135     DOI: 10.1007/bf00161246

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  7 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  The enigma of herpes stromal disease.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

4.  Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration.

Authors:  L M Collum; P McGettrick; J Akhtar; J Lavin; P J Rees
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

5.  Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

Authors:  L M Collum; A Benedict-Smith; I B Hillary
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

6.  Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study.

Authors:  W J Power; A Benedict-Smith; M Hillery; K Brady; L M Collum
Journal:  Curr Eye Res       Date:  1991       Impact factor: 2.424

7.  Acyclovir (Zovirax) in herpetic disciform keratitis.

Authors:  L M Collum; P Logan; T Ravenscroft
Journal:  Br J Ophthalmol       Date:  1983-02       Impact factor: 4.638

  7 in total
  4 in total

Review 1.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

Authors:  H B Hoh; C Hurley; C Claoue; M Viswalingham; D L Easty; P Goldschmidt; L M Collum
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 3.  Local delivery of corticosteroids in clinical ophthalmology: A review.

Authors:  Adrian T Fung; Tuan Tran; Lyndell L Lim; Chameen Samarawickrama; Jennifer Arnold; Mark Gillies; Caroline Catt; Logan Mitchell; Andrew Symons; Robert Buttery; Lisa Cottee; Krishna Tumuluri; Paul Beaumont
Journal:  Clin Exp Ophthalmol       Date:  2020-01-22       Impact factor: 4.207

Review 4.  Adoption of Innovation in Herpes Simplex Virus Keratitis.

Authors:  James Chodosh; Lawson Ung
Journal:  Cornea       Date:  2020-11       Impact factor: 3.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.